Gene:
FPGS
folylpolyglutamate synthase

PharmGKB contains no prescribing info for this . Contact us to report known genotype-based dosing guidelines, or if you are interested in developing guidelines.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

List of all variant annotations for FPGS

Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No Clinical Annotations available VA
rs10106 NC_000009.11:g.130576075T>C, NC_000009.12:g.127813796T>C, NG_009551.1:g.45973A>G, NG_023245.1:g.15922T>C, NM_001018078.2:c.*192T>C, NM_001288803.1:c.*192T>C, NM_004957.5:c.*192T>C, NR_110170.1:n.2004T>C, XM_005251863.1:c.*192T>C, XM_005251864.1:c.1484-412T>C, XM_005251864.2:c.1484-412T>C, XM_005251865.1:c.*192T>C, XM_011518437.1:c.*192T>C, XM_011518438.1:c.*192T>C, XM_011518439.1:c.*192T>C, XR_242581.1:n.1834T>C, XR_242581.2:n.1853T>C, XR_242582.1:n.1362-412T>C, XR_242582.2:n.1381-412T>C, rs16930111, rs3181756
T > -
T > C
SNP
No VIP available No Clinical Annotations available VA
rs1054774 NC_000009.11:g.130554998T>A, NC_000009.12:g.127792719T>A, NG_033942.1:g.11694T>A, rs3195291, rs58852618
T > A
SNP
No VIP available No Clinical Annotations available VA
rs10760502 NC_000009.11:g.130565267A>G, NC_000009.12:g.127802988A>G, NG_023245.1:g.5114A>G, NM_001018078.2:c.-429A>G, NM_001288803.1:c.64A>G, NM_004957.5:c.64A>G, NP_001275732.1:p.Ile22Val, NP_004948.4:p.Ile22Val, NR_110170.1:n.131A>G, XM_005251863.1:c.64A>G, XM_005251864.1:c.64A>G, XM_005251864.2:c.64A>G, XM_005251865.1:c.-1659A>G, XM_011518437.1:c.-570A>G, XM_011518438.1:c.-181A>G, XP_005251920.1:p.Ile22Val, XP_005251921.1:p.Ile22Val, XR_242581.1:n.90A>G, XR_242581.2:n.109A>G, XR_242582.1:n.90A>G, XR_242582.2:n.109A>G, rs17855899, rs56845445
A > -
A > G
SNP
I22V
No VIP available CA VA
rs1544105 NC_000009.11:g.130562725C>T, NC_000009.12:g.127800446C>T, NG_023245.1:g.2572C>T, rs56775301, rs60601426
C > T
SNP
No VIP available No Clinical Annotations available VA
rs4451422 NC_000009.11:g.130576597A>C, NC_000009.12:g.127814318A>C, NG_009551.1:g.45451T>G, NG_023245.1:g.16444A>C, NM_001018078.2:c.*714A>C, NM_001288803.1:c.*714A>C, NM_004957.5:c.*714A>C, NR_110170.1:n.2526A>C, XM_005251863.1:c.*714A>C, XM_005251864.1:c.*91A>C, XM_005251864.2:c.*91A>C, XM_005251865.1:c.*714A>C, XM_011518437.1:c.*714A>C, XM_011518438.1:c.*714A>C, XM_011518439.1:c.*714A>C, XM_011519273.1:c.-2261A>C, XR_242581.1:n.2356A>C, XR_242581.2:n.2375A>C, XR_242582.1:n.1472A>C, XR_242582.2:n.1491A>C, rs57484472
A > C
SNP
No VIP available CA VA
rs7856096 NC_000009.11:g.130566539A>G, NC_000009.12:g.127804260A>G, NG_023245.1:g.6386A>G, NM_001018078.2:c.-12-25A>G, NM_001288803.1:c.139-25A>G, NM_004957.5:c.139-25A>G, NR_110170.1:n.206-25A>G, XM_005251863.1:c.139-25A>G, XM_005251864.1:c.139-25A>G, XM_005251864.2:c.139-25A>G, XM_005251865.1:c.-387A>G, XM_011518437.1:c.-37A>G, XM_011518438.1:c.-12-25A>G, XR_242581.1:n.165-25A>G, XR_242581.2:n.184-25A>G, XR_242582.1:n.165-25A>G, XR_242582.2:n.184-25A>G, rs57202884
A > G
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Alternate Names:  None
Alternate Symbols:  None
PharmGKB Accession Id: PA167

Details

Cytogenetic Location: chr9 : q34.11 - q34.11
GP mRNA Boundary: chr9 : 130565137 - 130576799
GP Gene Boundary: chr9 : 130555137 - 130579799
Strand: plus

Visualization

UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Fluoropyrimidine Pathway, Pharmacodynamics
    Model non-tissue-specific cancer cell displaying genes which may be involved in the pharmacodynamics of the fluoropyrimidines, 5-fluorouracil (5-FU), capecitabine and tegafur.
  1. Methotrexate Pathway (Cancer Cell), Pharmacodynamics
    Methotrexate cellular disposition and effects.

Curated Information ?

Evidence Gene
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CDK9
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
ENG

Curated Information ?

Evidence Drug
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
methotrexate
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
warfarin

Curated Information ?

Publications related to FPGS: 23

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Are gene polymorphisms related to treatment outcomes of methotrexate in patients with rheumatoid arthritis? A systematic review and meta-analysis. Pharmacogenomics. 2017. Chen Yuehong, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ATIC missense variant affects response to methotrexate treatment in rheumatoid arthritis patients. Pharmacogenomics. 2016. Kurzawski Mateusz, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Impact of GGCX, STX1B and FPGS Polymorphisms on Warfarin Dose Requirements in European-Americans and Egyptians. Clinical and translational science. 2016. Hamadeh I S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Methotrexate pharmacokinetic genetic variants are associated with outcome in rheumatoid arthritis patients. Pharmacogenomics. 2016. Moya Patricia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Warfarin pharmacogenetics: it matters if you're black or white. Blood. 2014. Wadelius Mia. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic variant in folate homeostasis associated with lower warfarin dose in African Americans. Blood. 2014. Daneshjou Roxana, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients. The pharmacogenomics journal. 2012. Owen S A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer. International journal of cancer. Journal international du cancer. 2011. Nobili Stefania, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Systems pharmacology assessment of the 5-fluorouracil pathway. Pharmacogenomics. 2011. Muhale Filipe A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Purine biosynthetic pathway genes and methotrexate response in rheumatoid arthritis patients among north Indians. Pharmacogenetics and genomics. 2009. Sharma Shruti, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Aberrant splicing of folylpolyglutamate synthetase as a novel mechanism of antifolate resistance in leukemia. Blood. 2009. Stark Michal, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Resistance gene expression determines the in vitro chemosensitivity of non-small cell lung cancer (NSCLC). BMC cancer. 2009. Glaysher Sharon, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Interaction of genes from influx-metabolism-efflux pathway and their influence on methotrexate efficacy in rheumatoid arthritis patients among Indians. Pharmacogenetics and genomics. 2008. Sharma Shruti, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. The Journal of rheumatology. 2008. Ranganathan Prabha, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Folylpolyglutamate synthase and gamma-glutamyl hydrolase regulate leucovorin-enhanced 5-fluorouracil anticancer activity. Biochemical and biophysical research communications. 2008. Sakamoto Etsuko, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Identification and characterization of genetic variation in the folylpolyglutamate synthase gene. Cancer research. 2007. Leil Tarek A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Exploratory analysis of four polymorphisms in human GGH and FPGS genes and their effect in methotrexate-treated rheumatoid arthritis patients. Pharmacogenomics. 2007. van der Straaten R J H M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The use of low dose methotrexate in rheumatoid arthritis - are we entering a new era of therapeutic drug monitoring and pharmacogenomics?. Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie. 2006. Stamp Lisa, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Polymorphism discovery in 51 chemotherapy pathway genes. Human molecular genetics. 2005. Freimuth Robert R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. The Journal of clinical investigation. 2005. Kager Leo, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. International journal of cancer. Journal international du cancer. 2003. Liani Esti, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia. Blood. 1999. Rots M G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Phenytoin-induced depletion of folate in rats originates in liver and involves a mechanism that does not discriminate folate form. The Journal of nutrition. 1997. Carl G F, et al. PubMed

LinkOuts

NCBI Gene:
2356
OMIM:
136510
UCSC Genome Browser:
NM_004957
RefSeq RNA:
NM_001018078
NM_004957
RefSeq Protein:
NP_001018088
NP_004948
RefSeq DNA:
NG_023245
NT_008470
UniProtKB:
FOLC_HUMAN (Q05932)
Q5JU19_HUMAN (Q5JU19)
Ensembl:
ENSG00000136877
GenAtlas:
FPGS
GeneCard:
FPGS
MutDB:
FPGS
ALFRED:
LO006330M
HuGE:
FPGS
Comparative Toxicogenomics Database:
2356
ModBase:
Q05932
HumanCyc Gene:
HS06237
HGNC:
3824

Common Searches